L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study

Caroline Wass, Daniel Klamer, Evangelos Katsarogiannis, Erik Pålsson, Lennart Svensson, Kim Fejgin, Inga-Britt Bogren, Jörgen A Engel, Birgitta Rembeck, Caroline Wass, Daniel Klamer, Evangelos Katsarogiannis, Erik Pålsson, Lennart Svensson, Kim Fejgin, Inga-Britt Bogren, Jörgen A Engel, Birgitta Rembeck

Abstract

Background: Accumulating evidence suggests that the brain's nitric oxide (NO) signalling system may be involved in the pathophysiology of schizophrenia and could thus constitute a novel treatment target. The study was designed to investigate the benefit of L-lysine, an amino acid that interferes with NO production, as an add-on treatment for schizophrenia.

Methods: L-lysine, 6 g/day, was administered to 10 patients with schizophrenia as an adjunctive to their conventional antipsychotic medication. The study was designed as a single-blinded, cross-over study where patients were randomly assigned to initial treatment with either L-lysine or placebo and screened at baseline, after four weeks when treatment was crossed over, and after eight weeks.

Results: L-lysine treatment caused a significant increase in blood concentration of L-lysine and was well tolerated. A significant decrease in positive symptom severity, measured by the Positive And Negative Syndrome Scale (PANSS), was detected. A certain decrease in score was also observed during placebo treatment and the effects on PANSS could not unequivocally be assigned to the L-lysine treatment. Furthermore, performance on the Wisconsin Card Sorting Test was significantly improved compared to baseline, an effect probably biased by training. Subjective reports from three of the patients indicated decreased symptom severity and enhanced cognitive functioning.

Conclusions: Four-week L-lysine treatment of 6 g/day caused a significant increase in blood concentration of L-lysine that was well tolerated. Patients showed a significant decrease in positive symptoms as assessed by PANSS in addition to self-reported symptom improvement by three patients. The NO-signalling pathway is an interesting, potentially new treatment target for schizophrenia; however, the effects of L-lysine need further evaluation to decide the amino acid's potentially beneficial effects on symptom severity in schizophrenia.

Trial registration: ClinicalTrials.gov NCT00996242.

References

    1. Green MF, Braff DL. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications. Biol Psychiatry. 2001;49:374–384. doi: 10.1016/S0006-3223(00)01027-1.
    1. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41–51. doi: 10.1016/j.schres.2004.09.009.
    1. Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB, Fearing K. Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol. 1997;20:357–363. doi: 10.1097/00002826-199708000-00008.
    1. Klamer D, Engel JA, Svensson L. Phencyclidine-induced behaviour in mice prevented by methylene blue. Pharmacol Toxicol. 2004;94:65–72. doi: 10.1111/j.1742-7843.2004.pto940203.x.
    1. Seeman P, Guan HC, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse. 2009;63:698–704. doi: 10.1002/syn.20647.
    1. Pålsson E, Finnerty N, Fejgin K, Klamer D, Wass C, Svensson L, Lowry J. Increased cortical nitric oxide release after phencyclidine administration. Synapse. 2009;63:1083–1088.
    1. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. Clin Neuropharmacol. 2008;31:287–292. doi: 10.1097/WNF.0b013e3181593d45.
    1. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2010;71:138–149. doi: 10.4088/JCP.08m04666yel.
    1. Bernstein HG, Bogerts B, Keilhoff G. The many faces of nitric oxide in schizophrenia. A review. Schizophr Res. 2005;78:69–86.
    1. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–1308.
    1. Johansson C, Magnusson O, Deveney AM, Jackson DM, Zhang J, Engel JA, Svensson L. The nitric oxide snthase inhibitor, L-NAME, blocks certain phencyclidine-inducedbut not amphetamie-induced effects on behaviour and brain biochemisrty in the rat. Pro Neuro-Psychopharmacol Biol Psychiat. 1998;22:1341–1360. doi: 10.1016/S0278-5846(98)00074-8.
    1. Johansson C, Deveney AM, Reif D, Jackson DM. The neuronal selective nitric oxide inhibitor AR-R 17477, blocks some effects of phencyclidine, while having no observable behavioural effects when given alone. Pharmacol Toxicol. 1999;84:226–233. doi: 10.1111/j.1600-0773.1999.tb01487.x.
    1. Johansson C, Jackson DM, Svensson L. Nitric oxide synthase inhibition blocks phencyclidine-induced behavioural effects on prepulse inhibition and locomotor activity in the rat. Psychopharmacology (Berl) 1997;131:167–173. doi: 10.1007/s002130050280.
    1. Klamer D, Engel JA, Svensson L. The nitric oxide synthase inhibitor, L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology (Berl) 2001;156:182–186. doi: 10.1007/s002130100783.
    1. Klamer D, Pålsson E, Revesz A, Engel JA, Svensson L. Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms. Psychopharmacology (Berl) 2004;176:440–450. doi: 10.1007/s00213-004-1901-z.
    1. Klamer D, Pålsson E, Wass C, Archer T, Svensson L. Antagonism of the nitric oxide synthase inhibitor, L-NAME, of the effects of phencyclidine on latent inhibition in taste aversion conditioning. Behav Brain Res. 2005;161:60–68. doi: 10.1016/j.bbr.2005.01.008.
    1. Wass C, Archer T, Pålsson E, Fejgin K, Alexandersson A, Klamer D, Engel JA, Svensson L. Phencyclidine affects memory in a nitric oxide-dependent manner: Working and reference memory. Behav Brain Res. 2006;174:49–55. doi: 10.1016/j.bbr.2006.07.003.
    1. Wass C, Archer T, Pålsson E, Fejgin K, Klamer D, Engel JA, Svensson L. Effects of phencyclidine on spatial learning and memory: nitric oxide-dependent mechanisms. Behav Brain Res. 2006;171:147–153. doi: 10.1016/j.bbr.2006.03.036.
    1. Wass C, Klamer D, Fejgin K, Pålsson E. The importance of nitric oxide in social dysfunction. Behav Brain Res. 2009;200:113–116. doi: 10.1016/j.bbr.2009.01.002.
    1. Wass C, Svensson L, Fejgin K, Pålsson E, Archer T, Engel JA, Klamer D. Nitric oxide synthase inhibition attenuates phencyclidine-induced disruption of cognitive flexibility. Pharmacol Biochem Behav. 2008;89:352–359. doi: 10.1016/j.pbb.2008.01.011.
    1. White MF, Gazzola GC, Christensen HN. Cationic amino acid transport into cultured animal cells. I. Influx into cultured human fibroblasts. J Biol Chem. 1982;257:4443–4449.
    1. O'Kane RL, Viña JR, Simpson I, Zaragozá R, Mokashi A, Hawkins RA. Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+ Am J Physiol Endocrinol Metab. 2006;291:E412–419.
    1. Closs EI, Basha FZ, Habermeier A, Förstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide. 1997;1:65–73. doi: 10.1006/niox.1996.0106.
    1. Carter BW Jr, Chicoine LG, Nelin LD. L-lysine decreases nitric oxide production and increases vascular resistance in lungs isolated from lipopolysaccharide-treated neonatal pigs. Pediatr Res. 2004;55:979–987. doi: 10.1203/01.pdr.0000127722.55965.b3.
    1. Pålsson E, Fejgin K, Wass C, Engel JA, Svensson L, Klamer D. The amino acid L-lysine blocks the disruptive effect of phencyclidine on prepulse inhibition in mice. Psychopharmacology (Berl) 2007;192:9–15.
    1. Finnerty NJ. PhD thesis. National University of Ireland, Maynooth, Department of Chemistry; 2008. Electrochemical sensors: in-vitro and in-vivo analysis of brain nitric oxide and regional cerebral blood flow.
    1. Griffith RS, Norins AL, Kagan C. A multicentered study of lysine therapy in Herpes simplex infection. Dermatologica. 1978;156:257–267. doi: 10.1159/000250926.
    1. Civitelli R, Villareal DT, Agnusdei D, Nardi P, Avioli LV, Gennari C. Dietary L-lysine and calcium metabolism in humans. Nutrition. 1992;8:400–405.
    1. Izquierdo OA, Parsons CM, Baker DH. Bioavailability of lysine in L-lysine.HCl. J Anim Sci. 1988;66:2590–2597.
    1. Flodin NW. The metabolic roles, pharmacology, and toxicology of lysine. J Am Coll Nutr. 1997;16:7–21.
    1. Spencer H, Samachson J. Effect of lysine on calcium metabolism in man. J Nutr. 1963;81:301–306.
    1. Luckey EH, Rubin AL. The correction of hyponatremia in congestive heart failure. Circulation. 1960;21:229–235.
    1. Anderson SR, Raiten CJ. Safety of Amino Acids Used as Dietary Supplements. Life Sciences Research Office, Bethesda, MD: FASEB Special Publications Office; 1992. p. 22.
    1. Moore S, Stein WH. A modified ninhydrin reagent for the photometric determination of amino acids and related compounds. J Biol Chem. 1954;211:907–913.
    1. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64:1115–1122. doi: 10.1001/archpsyc.64.10.1115.
    1. Goldman-Rakic PS. Development of cortical circuitry and cognitive function. Child Dev. 1987;58:601–622. doi: 10.2307/1130201.
    1. Green MF, Schooler NR, Kern RS, Frese FJ, Granberry W, Harvey PD, Karson CN, Peters N, Stewart M, Seidman LJ, Sonnenberg J, Stone WS, Walling D, Stover E, Marder SR. Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Am J Psychiatry. 2011. in press .
    1. Harvey PD. Pharmacological cognitive enhancement in schizophrenia. Neuropsychol Rev. 2009;19:324–335. doi: 10.1007/s11065-009-9103-4.
    1. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203–213. doi: 10.1176/appi.ajp.2007.07010042.
    1. Harvey PD, Palmer BW, Heaton RK, Mohamed S, Kennedy J, Brickman A. Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study. Am J Psychiatry. 2005;162:110–117. doi: 10.1176/appi.ajp.162.1.110.
    1. DeLisi LE, Szulc KU, Bertisch HC, Majcher M, Brown K. Understanding structural brain changes in schizophrenia. Dialogues Clin Neurosci. 2006;8:71–78.
    1. Eack SM, Hogarty GE, Cho RY, Prasad KM, Greenwald DP, Hogarty SS, Keshavan MS. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry. 2010;67:674–682. doi: 10.1001/archgenpsychiatry.2010.63.
    1. Kandel ER. The molecular biology of memory storage: a dialog between genes and synapses. Biosci Rep. 2004;24:475–522. doi: 10.1007/s10540-005-2742-7.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever